Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism

Archives of Internal Medicine

Volumn 158, Issue 9, 1998, Pages 1005-1010

  White, Richard H ^a   Zhou, Hong ^a   Romano, Patrick S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; WARFARIN;

AGE; ARTICLE; CANCER; DEEP VEIN THROMBOSIS; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIMB FRACTURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE TRAUMA; ORAL DRUG ADMINISTRATION; PELVIS FRACTURE; PRIORITY JOURNAL; RECURRENCE RISK; SEX DIFFERENCE; SURGERY; THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HUMANS; INCIDENCE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; THROMBOPHLEBITIS; WARFARIN;

EID: 0032507784     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.9.1005     Document Type: Article

References (19)

1. Hyers TM, Weg JG. Antithrombotic therapy for venous thromboembolism. Chest. 1995;108:(suppl 4):335S-351S.
2. Meux E. Encrypting personal identifiers. Health Serv Res. 1994;29:247-256.
3. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
4. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
5. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. JClin Epidemiol. 1993;46:1075-1079.
6. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
7. Wessler S, Gitel SN. Warfarin: from bedside to bench. N Engl J Med. 1984;311:645-652.
8. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest, 1993;92:2131-2140.
9. Hirsh J, Fuster V. Guide to anticoagulant therapy, II: oral anticoagulants -American Heart Association. Circulation. 1994;89:1469-1480,
10. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997;126:133-136.
11. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Gate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
12. Nicholls SC, O'Brian JK, Sutton MG. Venous thromboembolism: detection by duplex scanning. J Vasc Surg. 1996;23:511-516.
13. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state. Lancet. 1991;338:1079.
14. Nemerson Y. Tissue factor and the initiation of blood coagulation. Adv Exp Med Biol. 1987;214:83-94.
15. Meux EF, Stith SA, Zach A. Report of Results From the OSHPD Reabstracting Project: An Evaluation of the Reliability of Selected Patient Discharge Data, July Through December 1988. Sacramento, Calif: Office of Statewide Health Planning and Development; 1990.
16. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
17. The Columbus Investigators. Low molecular-weight heparin in the treatment of patients with venous thrombosis. N Engl J Med. 1997;337:657-662.
18. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
19. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-1665.